La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

NantHealth Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di NantHealth.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Healthcare Services crescita degli utili	30.8%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Investors Aren't Buying NantHealth, Inc.'s (NASDAQ:NH) Revenues

Apr 17

NantHealth GAAP EPS of -$0.11, revenue of $16.5M

Aug 04

Ronald Louks Is The Chief Operating Officer of NantHealth, Inc. (NASDAQ:NH) And They Just Sold 26% Of Their Shares

Mar 18

Time To Worry? Analysts Are Downgrading Their NantHealth, Inc. (NASDAQ:NH) Outlook

Mar 06

If You Had Bought NantHealth (NASDAQ:NH) Shares A Year Ago You'd Have Earned 183% Returns

Feb 04

NantHealth jumps after study highlights the utility of its decision-support platform

Dec 11

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché NantHealth non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:NHIQ - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2023	64	-70	-32	-28	N/A
6/30/2023	68	-69	-31	-25	N/A
3/31/2023	68	-64	-34	-28	N/A
12/31/2022	67	-68	-39	-32	N/A
9/30/2022	66	-59	-36	-31	N/A
6/30/2022	63	-56	-37	-31	N/A
3/31/2022	63	-59	-34	-29	N/A
12/31/2021	63	-58	-33	-28	N/A
9/30/2021	65	-62	-29	-23	N/A
6/30/2021	70	-62	-29	-23	N/A
3/31/2021	71	-95	-30	-24	N/A
12/31/2020	73	-88	-23	-17	N/A
9/30/2020	73	-81	-24	-18	N/A
6/30/2020	73	-86	-15	-10	N/A
3/31/2020	75	-55	-11	-7	N/A
12/31/2019	77	-65	-13	-9	N/A
9/30/2019	82	-101	-14	-10	N/A
6/30/2019	85	-183	-23	-15	N/A
3/31/2019	87	-188	-32	-21	N/A
12/31/2018	89	-190	-40	-30	N/A
9/30/2018	89	-164	-44	-34	N/A
6/30/2018	88	-89	-59	-50	N/A
3/31/2018	90	-125	-75	-68	N/A
12/31/2017	87	-131	-95	-81	N/A
9/30/2017	82	-157	-108	-92	N/A
6/30/2017	81	-161	N/A	-84	N/A
3/31/2017	80	-138	N/A	-65	N/A
12/31/2016	80	-145	N/A	-71	N/A
9/30/2016	83	-131	N/A	-74	N/A
6/30/2016	77	-128	N/A	-85	N/A
3/31/2016	66	-110	N/A	-91	N/A
12/31/2015	46	-62	N/A	-74	N/A
9/30/2015	48	-84	N/A	-63	N/A
6/30/2015	43	-91	N/A	-53	N/A
3/31/2015	39	-86	N/A	-47	N/A
12/31/2014	34	-84	N/A	-42	N/A
12/31/2013	27	-41	N/A	-16	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista NHIQ è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di NHIQ cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di NHIQ cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di NHIQ cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di NHIQ cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di NHIQ è previsto essere elevato tra 3 anni

NantHealth Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased to US$3.25

Consensus EPS estimates fall by 18%

Consensus EPS estimates fall to -US$0.52

Analysts lower EPS estimates to -US$0.52

Price target lowered to US$3.75

Analysts lower EPS estimates to -US$0.55

Recent updates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

Summus Holdings Engages in Discussions with NantHealth

NantHealth, Inc. Announces Executive Changes

Nant Capital Engages in Discussions with NantHealth

NantHealth, Inc. announced delayed 10-Q filing

NantHealth, Inc.(NasdaqGS:NH) dropped from S&P TMI Index

NantHealth Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Publicly Held Shares Requirement

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

NantHealth Receives Written Notice from Nasdaq Stating the Company Has Not Complied with the Public Float Requirement Prior to the Expiration of the Compliance Period

Investors Aren't Buying NantHealth, Inc.'s (NASDAQ:NH) Revenues

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

NantHealth, Inc. Receives Written Notice from Nasdaq

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth GAAP EPS of -$0.11, revenue of $16.5M

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings: EPS misses analyst expectations

NantHealth, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$3.25

Consensus EPS estimates fall by 18%

NantHealth, Inc. Receives Notice from the Nasdaq Stock Market LLC

Full year 2021 earnings: EPS exceeds analyst expectations

NantHealth, Inc. to Report Q4, 2021 Results on Feb 24, 2022

NantHealth, Inc. Announces Not Stand for Re-Election of Michael S. Sitrick as Member of the Board Directors

Third quarter 2021 earnings released: US$0.094 loss per share (vs US$0.099 loss in 3Q 2020)

Chief Operating Officer notifies of intention to sell stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.43 loss in 2Q 2020)

Consensus EPS estimates fall to -US$0.52

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.081 loss in 1Q 2020)

NantHealth, Inc. Launches Eviti Connect for Autoimmune Diseases

Founder recently bought US$5.0m worth of stock

NantHealth, Inc. announced that it expects to receive $137.5 million in funding from Nant Capital, LLC, Highbridge Capital Management, LLC

Ronald Louks Is The Chief Operating Officer of NantHealth, Inc. (NASDAQ:NH) And They Just Sold 26% Of Their Shares

Chief Operating Officer recently sold US$297k worth of stock

Time To Worry? Analysts Are Downgrading Their NantHealth, Inc. (NASDAQ:NH) Outlook

Analysts lower EPS estimates to -US$0.52

Full year 2020 earnings released: US$0.80 loss per share (vs US$0.57 loss in FY 2019)

Revenue and earnings miss expectations

NantHealth, Inc. to Report Q4, 2020 Results on Feb 25, 2021

If You Had Bought NantHealth (NASDAQ:NH) Shares A Year Ago You'd Have Earned 183% Returns

New 90-day high: US$4.07

NantHealth, Inc. and Sesame Announces Collaboration to Help Providers Increase Productivity and Better Serve Patients

New 90-day high: US$3.67

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NantHealth jumps after study highlights the utility of its decision-support platform

New 90-day high: US$2.81

Price target lowered to US$3.75

NantHealth, Inc. and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Third quarter 2020 earnings released: US$0.099 loss per share

Revenue beats expectations, earnings disappoint

NantHealth, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$2.01

NantHealth, Inc. to Report Q2, 2019 Results on Aug 08, 2019

NantHealth, Inc. Enhances Interoperability of the Navinet Open Platform with Expanded API Capabilities

NantHealth, Inc. Rolls Out Navinet AllPayer Platform Nationally

New 90-day low: US$2.39

New 90-day low - US$2.60

Analysts lower EPS estimates to -US$0.55

First half earnings released

NantHealth, Inc. to Report Q2, 2020 Results on Aug 06, 2020

NantHealth, Inc. (NasdaqGS:NH) acquired The OpenNMS Group, Inc. Cambridge Equities, LP.